Structure Database (LMSD)

Introduction | Text/ontology-based search | Structure-based search | Programmatic Access

LMSD: Lipid classification search results

Prenol Lipids [PR] (W) --> Isoprenoids [PR01]--> C15 isoprenoids (sesquiterpenes) [PR0103]
LM_IDCommon NameSystematic NameFormulaMass
LMPR0103010000Farnesane skeleton---
LMPR01030100012E,6E-farnesol (W)2E,6E-farnesolC15H26O222.1984
LMPR0103010002Farnesyl diphosphate (W)Farnesyl pyrophosphateC15H28O7P2382.1310
LMPR0103010003Nerolidyl diphosphateNerolidyl pyrophosphateC15H28O7P2382.1310
LMPR0103010004Juvenile hormone III (W)-C16H26O3266.1882
LMPR0103010005Nerolidol (W)-C15H26O222.1984
LMPR01030100062E,6Z-farnesol3,7,11-trimethyldodeca-2E,6Z,10-trien-
1-ol
C15H26O222.1984
LMPR01030100072E,6Z-farnesal3,7,11-trimethyldodeca-2Z,6E,10-trienalC15H24O220.1827
LMPR0103010008(2-cis,6-cis)-farnesol(2Z,6Z)-3,7,11-trimethyldodeca-2,6,10-
trien-1-ol
C15H26O222.1984
LMPR01030100092-cis,6-cis-farnesyl diphosphate(2Z,6Z)-3,7,11-trimethyldodeca-2,6,10-
trien-1-yl trihydrogen diphosphate
C15H28O7P2382.1310
LMPR01030100102-cis,6-trans-farnesyl diphosphate(2Z,6E)-3,7,11-trimethyldodeca-2,6,10-
trien-1-yl trihydrogen diphosphate
C15H28O7P2382.1310
LMPR01030100112-trans,6-cis-farnesyl diphosphate(2E,6Z)-3,7,11-trimethyldodeca-2,6,10-
trien-1-yl trihydrogen diphosphate
C15H28O7P2382.1310
LMPR0103010012(2-trans,6-trans)-farnesal(2E,6E)-3,7,11-trimethyldodeca-2,6,10-
trienal
C15H24O220.1827
LMPR0103010013(2-cis,6-trans)-farnesol3,7,11-trimethyldodeca-2Z,6E,10-trien-
1-ol
C15H26O222.1984
LMPR010301001414:0(5Me[R],9Me[R],13Me)5R,9R,13-trimethyl-tetradecanoic acidC17H34O2270.2559
LMPR010301001518:1(5Z)(9Me,13Me,17Me)9,13,17-trimethyl-5Z-octadecenoic acidC21H40O2324.3028
LMPR010301001620:1(5Z)(11Me,15Me,19Me)11,15,19-trimethyl-5Z-eicosenoic acidC23H44O2352.3341
LMPR010301001722:1(5Z)(13Me,17Me,21Me)13,17,21-trimethyl-5Z-docosenoic acidC25H48O2380.3654
LMPR010301001820:2(5Z,9Z)(11Me,15Me,19Me)11,15,19-trimethyl-5Z,9Z-eicosadienoic
acid
C23H42O2350.3185
LMPR010301001922:2(5Z,9Z)(13Me,17Me,21Me)13,17,21-trimethyl-5Z,9Z-docosadienoic
acid
C25H46O2378.3498
LMPR010301002020:3(5Z,9Z,17Z)(11Me,15Me,19Me)11,15,19-trimethyl-5Z,9Z,17Z-
eicosatrienoic acid
C23H40O2348.3028
LMPR010301002122:3(5Z,9Z,19Z)(13Me,17Me,21Me)13,17,21-trimethyl-5Z,9Z,19Z-
docosatrienoic acid
C25H44O2376.3341
LMPR010301002224:3(5Z,9Z,17Z)(15Me,19Me,23Me)15,19,23-trimethyl-5Z,9Z,17Z-
tetracosatrienoic acid
C27H48O2404.3654
LMPR0103010023farnesyl triphosphate3,7,11-trimethyldodeca-2,6,10-trien-1-
yl tetrahydrogen triphosphate
C15H29O10P3462.0974
LMPR0103010024-13-bromo-10R,11R-dichloro-7,11-
dimethyl-3-methylene-4-oxo-6E,8E,12E-
tridecatrienoic acid
C16H19BrCl2O3407.9895
LMPR0103010025-13-bromo-10S,11R-dichloro-7,11-
dimethyl-3-methylene-4-oxo-6E,8E,12E-
tridecatrienoic acid
C16H19BrCl2O3407.9895
LMPR0103010026-10S,11R-dichloro-7,11-dimethyl-3-
methylene-4R-hydroxy-6E,8E,12-
tridecatrienoic acid
C16H22Cl2O3332.0946
LMPR0103010027-13-bromo-10R,11R-dichloro-7,11-
dimethyl-3-methylene-4R-hydroxy-6E,8E,
12E-tridecatrienoic acid
C16H21BrCl2O3410.0051
LMPR0103020001Ngaione (-)(2'S,5'R)-4-methyl-l-(5'-methyl-2',3',
4',5'-tetrahydro[2' ',3' '-bifuran]-5'-
yl)pentan-2-one
C15H22O3250.1569
LMPR0103030001-6,10-dimethyl-9-methylene-5E-undecen-2-
one
C14H24O208.1827
LMPR0103030002(R)-Sesquilavandulol5,9-dimethyl-2R-(prop-1-en-2-yl)deca-
4E,8-dien-1-ol
C15H26O222.1984
LMPR0103040001Valerenal-C15H22O218.1671
LMPR0103050001(S)-(+)-Abscisic acid (W)-C15H20O4264.1362
LMPR0103050002(-)-abscisic aldehyde(2Z,4E)-5-[(1R)-1-hydroxy-2,6,6-
trimethyl-4-oxocyclohex-2-en-1-yl]-3-
methylpenta-2,4-dienal
C15H20O3248.1412
LMPR0103050003Latia luciferin(1E)-2-methyl-4-(2,6,6-
trimethylcyclohex-1-en-1-yl)but-1-enyl
formate
C15H24O2236.1776
LMPR0103050004abscisic aldehyde(2Z,4E)-5-(1-hydroxy-2,6,6-trimethyl-4-
oxocyclohex-2-en-1-yl)-3-methylpenta-2,
4-dienal
C15H20O3248.1412
LMPR0103050005dihydrophaseic acid(2Z,4E)-5-[(1R,3S,5R,8S)-3,8-dihydroxy-
1,5-dimethyl-6-oxabicyclo[3.2.1]oct-8-
yl]-3-methylpenta-2,4-dienoic acid
C15H22O5282.1467
LMPR0103050006dihydrophaseic acid 4-O-β-D-glucoside(2Z,4E)-5-[(1R,3S,5R,8S)-3-(β-D-
glucopyranosyloxy)-8-hydroxy-1,5-
dimethyl-6-oxabicyclo[3.2.1]oct-8-yl]-
3-methylpenta-2,4-dienoic acid
C21H32O10444.1996
LMPR0103050007epi-dihydrophaseic acid(2Z,4E)-5-[(1R,3R,5R,8S)-3,8-dihydroxy-
1,5-dimethyl-6-oxabicyclo[3.2.1]oct-8-
yl]-3-methylpenta-2,4-dienoic acid
C15H22O5282.1467
LMPR0103050008(-)-abscisic acid (W)(2Z,4E)-5-[(1R)-1-hydroxy-2,6,6-
trimethyl-4-oxocyclohex-2-en-1-yl]-3-
methylpenta-2,4-dienoic acid
C15H20O4264.1362
LMPR0103050009(6S)-dehydrovomifoliol(4S)-4-hydroxy-3,5,5-trimethyl-4-[(1E)-
3-oxobut-1-en-1-yl]cyclohex-2-en-1-one
C13H18O3222.1256
LMPR0103050010(+)-8'-hydroxyabscisic acid(2Z,4E)-5-[(1R,6R)-1-hydroxy-6-
(hydroxymethyl)-2,6-dimethyl-4-
oxocyclohex-2-en-1-yl]-3-methylpenta-2,
4-dienoic acid
C15H20O5280.1311
LMPR0103050011(+)-abscisic acid β-D-glucopyranosyl
ester
1-O-{(2Z,4E)-5-[(1S)-1-hydroxy-2,6,6-
trimethyl-4-oxocyclohex-2-en-1-yl]-3-
methylpenta-2,4-dienoyl}-β-D-
glucopyranose
C21H30O9426.1890
LMPR0103050012(R)-2-trans-abscisic acid(2E,4E)-5-[(1R)-1-hydroxy-2,6,6-
trimethyl-4-oxocyclohex-2-en-1-yl]-3-
methylpenta-2,4-dienoic acid
C15H20O4264.1362
LMPR01030500131'-deoxyabscisic acid3-methyl-5-(2,6,6-trimethyl-4-
oxocyclohex-2-en-1-yl)-2Z,4E-
pentadienoic acid
C15H20O3248.1412
LMPR01030500147'-hydroxyabscisic acid(2Z,4E)-5-[1-hydroxy-2-(hydroxymethyl)-
6,6-dimethyl-4-oxocyclohex-2-en-1-yl]-
3-methylpenta-2,4-dienoic acid
C15H20O5280.1311
LMPR0103060000Bisabolane skeleton1-(1,5-Dimethylhexyl)-4-
methylcyclohexane
--
LMPR0103060001(-)-α-Bisabolol-C15H26O222.1984
LMPR0103060002Zingiberene (W)-C15H24204.1878
LMPR0103060003fumagillin (W)(2E,4E,6E,8E)-10-({(3R,4S,5S,6R)-5-
methoxy-4-[(2R,3R)-2-methyl-3-(3-
methylbut-2-en-1-yl)oxiran-2-yl]-1-
oxaspiro[2.5]oct-6-yl}oxy)-10-oxodeca-
2,4,6,8-tetraenoic acid
C26H34O7458.2305

Showing page 1 of 6     Results:    1  2  3  4  5  Next  Last     Showing results 1 to 50 of 276

   

logo LIPID MAPS is funded by a Wellcome Trust.